Apigenin, the flavonoid concentrated in chamomile, parsley, and celery, has attracted growing interest for sleep, calm, anti-inflammatory and NAD+ claims that rest mostly on cell and animal work. Supplement shelves now carry standalone apigenin capsules, and many wellness routines include chamomile tea daily. For most healthy adults, chamomile is likely safe orally in the amounts found in teas, but supplement doses have no long-term human safety data [8]. Pregnancy, however, changes every pharmacological calculation: what crosses the placenta, what influences uterine tone, and what disrupts fetal hormone signaling must all be weighed with far greater care.
Direct, controlled human trials on apigenin supplementation during pregnancy do not exist. What researchers and clinicians must work from instead is a patchwork of indirect evidence: studies on chamomile (apigenin’s richest dietary source), broader reviews of flavonoid supplements in pregnancy, animal toxicology data on structurally similar compounds, and mechanistic reasoning about apigenin’s known pharmacological actions. That patchwork, taken together, is enough to warrant real caution, even if it stops short of a definitive prohibition. This article assembles that evidence honestly, without overstating either the danger or the safety.
Key Takeaways
- Clinical studies on chamomile, apigenin’s richest source, have looked at labor onset and uterine contractions; the oral post-term trial suggests a biologically plausible mechanism for concern during pregnancy, while the odor trial found no effect on contraction number or duration [1][2].
- A literature review of flavonoid supplements in pregnancy found that supplement-level doses cannot be assumed safe for the developing fetus, citing topoisomerase inhibition, placental transfer, and hormonal activity as concerns [3].
- Apigenin’s weak estrogenic activity and interaction with reproductive signaling pathways, as noted in endometriosis research [4], add a hormonal dimension to the pregnancy caution.
- Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4, which can raise blood levels of co-administered medications: a meaningful risk during pregnancy when polypharmacy is common.
- No direct, controlled human trials on isolated apigenin supplementation in pregnancy exist; the current evidence base is indirect and insufficient to establish safety at supplement doses.
What Apigenin Is and Why Pregnancy Changes the Risk Calculation
Apigenin (4′,5,7-trihydroxyflavone) is a naturally occurring plant flavonoid that exerts several pharmacological effects at meaningful doses. It bound benzodiazepine sites in rat brain binding assays, but in cell work it inhibited GABA activation on its own without acting through that site, so sedation and anxiolysis are not established. In cell studies it is reported to inhibit cyclin-dependent kinases CDK2 and CDK6 and trigger apoptosis in rapidly dividing cells. In a purified enzyme assay it also inhibited CD38, an enzyme that consumes NAD+ [9][10][11][12]. At typical dietary amounts from food, these effects are unlikely to reach clinically significant thresholds. At the concentrated doses found in modern supplements, often 50 mg to 100 mg per capsule, the picture becomes less certain.
Pregnancy amplifies every pharmacological concern in predictable ways. The developing fetus lacks the full complement of metabolic enzymes needed to process xenobiotics, so compounds that an adult clears quickly can accumulate in fetal tissue. Hormonal signaling is exquisitely sensitive during organogenesis and later stages of fetal brain development; flavonoids with weak estrogenic activity, including apigenin, may interfere with those signals. Uterine contractility is tightly regulated throughout pregnancy, and any agent that influences smooth muscle tone or prostaglandin pathways deserves scrutiny. Finally, apigenin’s anti-proliferative activity in cancer cell studies is a theoretical concern for a fetus, whose development depends on rapid, coordinated cell division, and no study in the evidence tests this for apigenin.
Chamomile, Apigenin's Primary Food Source, and Uterine Effects
Chamomile tea is a common way people consume apigenin, and two clinical studies of chamomile are relevant to pregnancy. An Iranian trial in 80 first-time mothers at 40 weeks or later gave chamomile capsules, not tea, that were not standardised to apigenin. Labor began within a week in 92.5% of the chamomile group versus 62.5% on placebo, suggesting a possible uterine-stimulating effect [1]. While this was framed as a potential benefit for post-term induction, the same mechanism is clearly undesirable earlier in gestation when premature labor is the risk being guarded against.
In 80 post-term first-time mothers, labour began within a week for 92.5% on chamomile capsules versus 62.5% on placebo
Chamomile capsules were followed by earlier labour onset, which is why chamomile warrants caution late in pregnancy.
Double-blind trial in first-time mothers at 40 weeks or more, chamomile 500 mg capsules, 2 capsules every 8 hours for up to 7 days. Capsules, not tea. Source: Gholami et al., Iranian Red Crescent medical journal 2016
Data table
| Item | Value |
|---|---|
| Chamomile capsules | 92.5% |
| Placebo (corn starch) | 62.5% |
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Research note: In a Canadian case-control analysis cited by EMA, chamomile use in the last two trimesters was not linked to preterm delivery after adjusting for confounders [22].
A separate clinical trial examined the effect of chamomile odor, an aromatherapy exposure far lower than oral ingestion, on uterine contractions during the first stage of labor and found no effect on the number or duration of contractions in first-time mothers, though contraction intensity was lower at 5-7 cm of dilatation [2]. That result does not suggest uterine stimulation from odor exposure, so the concern rests mainly on the oral chamomile trial, and concentrated oral supplementation of the active compound carries greater uncertainty. Taken together, these two studies do not establish that apigenin causes miscarriage or preterm labor, and only the oral chamomile trial points toward uterine stimulation, but that finding provides biological plausibility that makes high-dose apigenin supplementation during pregnancy difficult to recommend.
It is worth noting that neither study was designed to test apigenin in isolation, and chamomile contains many bioactive constituents beyond apigenin. Still, authors reviewing chamomile trials say it is hard to tell whether apigenin, other components, or both drive the effects, so the precautionary logic rests on chamomile as a whole, not on apigenin alone [13][14].
What Broader Flavonoid Research Suggests About Supplement Use in Pregnancy
A literature review published in Current Drug Targets examined whether flavonoid-based food supplements are safe for the developing child when taken during pregnancy [3]. The review identified several concerns: flavonoids can cross the placenta and reach fetal circulation; some flavonoids act as topoisomerase II inhibitors, raising theoretical concerns about infant leukemia risk at high doses; and the hormonal activity of various flavonoids, including their weak estrogenicity, may interfere with fetal reproductive development. The authors concluded that safety for the developing child cannot be assumed, and that supplemental doses above normal dietary exposure deserve scrutiny before being considered safe in pregnancy [3].
Apigenin was not the sole focus of that review, but it shares the structural and mechanistic features that drove the authors’ concerns. It is a polyphenol with weak estrogenic activity. Topoisomerase II inhibition is a concern named for the flavonoid class, and no study in the evidence shows it for apigenin in pregnancy. Supplement doses are larger than dietary amounts, but pure apigenin was poorly absorbed in healthy men, so blood levels from supplements are unknown. This does not mean apigenin at those doses is definitively harmful, only that the concerns raised for the flavonoid class have not been tested for apigenin in pregnancy [15][3].
Animal and Preclinical Data: Early Signals Worth Understanding
Preclinical toxicology data on apigenin itself in pregnancy is sparse, but data from structurally related flavonoids and plant extracts containing apigenin offer useful context. A prenatal developmental toxicity evaluation of Verbena officinalis, a flavonoid-rich herb, during gestation in Sprague-Dawley rats documented signs of developmental concern at higher doses, including effects on fetal body weight and placental parameters [5]. While Verbena contains a range of bioactive compounds and cannot be equated directly to isolated apigenin, the study illustrates that flavonoid-dense botanical preparations can produce measurable developmental effects in animal models.
A 2025 systematic review examining the impact of ginger extract and alpinetin on pregnancy outcomes in animal models found that certain plant-derived bioactives can alter fetal development parameters in ways that are dose- and timing-dependent [6]. The relevance to apigenin is indirect but instructive: plant compounds often considered gentle or natural do register pharmacological signals in pregnant animal models, and those signals are not always benign at higher doses.
Research on quercetin, a structurally related flavonoid, has examined its effects on hypertension and pregnancy-induced hypertension, finding both potential benefits and the need for careful dosing consideration during pregnancy [7]. Quercetin and apigenin share core flavonoid scaffold features and several mechanisms, but that review is about quercetin, so the cautious framing is an analogy and not evidence about apigenin.
Hormonal and Endocrine Considerations
Apigenin has been identified in preclinical studies as a phytoestrogen: a plant compound that can bind estrogen receptors and modulate estrogen-dependent signaling. A review examining plants as potential therapies for endometriosis noted that several flavonoids, including apigenin, interact with estrogen receptor pathways in ways that can influence reproductive tissue [4]. During pregnancy, estrogen signaling governs placental development, fetal organ maturation, and the timing of parturition. Any exogenous compound that modulates estrogen receptor activity introduces a variable into that tightly choreographed system.
The concern is not that apigenin floods the system with estrogen the way synthetic hormones might. The concern is subtler: at supplemental concentrations, weak estrogenic or anti-estrogenic activity on fetal tissue, particularly during sensitive developmental windows, could have effects that are not immediately observable but matter downstream. Human data to quantify this risk does not exist for apigenin specifically, which is precisely why the precautionary argument holds weight.
Animal findings on apigenin’s estrogen-like action are mixed. In ovariectomised and estrogenised mice it acted as a partial estrogen-receptor agonist, and in rats apigenin and luteolin raised uterine weight and showed anti-implantation activity. Yet in immature rats, 50 mg/kg given by mouth did not cause uterine growth, which the authors linked to poor absorption or bioavailability [23][24][25].
Drug Interactions Amplified During Pregnancy
In lab tests apigenin inhibits cytochrome P450 enzymes CYP1A2, CYP2C9, and CYP3A4, the same enzymes that metabolize a wide range of medications. No clinical study in the evidence tests whether apigenin changes drug levels in people, pregnant or not, so this remains a theoretical concern [16][17][18][19]. During pregnancy, where dosing is already complicated by altered plasma volume, slower gastric emptying, and the pharmacokinetic needs of two individuals rather than one, adding an enzyme inhibitor raises the risk of unintended drug interactions considerably.
This concern applies to everyday co-exposures as well. Apigenin stacks poorly with other sedatives (melatonin, antihistamines, or alcohol) in any population. During pregnancy, combining apigenin with other sedating agents is a precaution worth discussing with a clinician, although apigenin’s own sedative effect in people has not been shown [20]. Anyone taking any prescription medication during pregnancy and considering apigenin supplementation should discuss the interaction risk with their prescribing physician before proceeding.
A Note on the Evidence
The evidence reviewed here is indirect: no controlled human trials on isolated apigenin supplementation in pregnancy exist, and most data derives from chamomile studies, animal models, or analogous flavonoids. The absence of proof of harm is not proof of safety, particularly during pregnancy. Pregnant individuals, those trying to conceive, and those on medications metabolized by CYP1A2, CYP2C9, or CYP3A4 should consult a qualified healthcare provider before using apigenin supplements. These statements have not been evaluated by the FDA; apigenin is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
Is chamomile tea safe during pregnancy?
Chamomile tea is a common apigenin source, and two studies of chamomile are relevant: one linked chamomile capsules, not tea, to labor onset in post-term pregnancies [1], and another examined chamomile odor during the first stage of labor and found no effect on the number or duration of contractions, though intensity was lower at 5-7 cm of dilatation [2]. The EU herbal monograph states that safety in pregnancy is established for chamomile herbal tea but not for extract preparations, and its assessors noted that large questionnaire studies of pregnant women showed no risk from tea, though those are self-reported usage surveys [1][21][22][2]. Consult your midwife or OB for personalized guidance.
Can apigenin supplements cause miscarriage?
There are no controlled human studies that establish a direct causal link between apigenin supplementation and miscarriage. However, the labor-stimulating effect of oral chamomile in one trial, and the contraction findings in another [1][2] and the broader concerns about flavonoid supplements during pregnancy [3] provide biological plausibility for uterine effects. This does not prove causation, but it is sufficient reason to avoid high-dose supplementation, particularly in the first trimester, until more direct safety data exists.
Are all flavonoids equally risky during pregnancy?
No: the risk profile varies by compound, dose, and trimester. A literature review examining flavonoid-based supplements during pregnancy found that concerns include topoisomerase II inhibition and hormonal activity, but these differ in degree across the flavonoid family [3]. Research on related flavonoids like quercetin notes that dosing context matters significantly for pregnancy safety considerations [7]. Apigenin shares several of the concerning mechanisms, so it cannot be assumed safer than its class.
Does apigenin affect fetal hormones?
Apigenin has phytoestrogenic activity and has been noted to interact with estrogen receptor pathways in reproductive tissue contexts, as highlighted in research on plant-based approaches to endometriosis [4]. During fetal development, estrogen signaling governs organ formation and reproductive tract maturation. While the magnitude of apigenin’s estrogenic effect is modest compared to synthetic estrogens, the sensitivity of fetal tissue to hormonal signals means even modest interference is a theoretical concern worth taking seriously.
What about apigenin from food rather than supplements during pregnancy?
Dietary apigenin from parsley, celery, and chamomile tea represents a far lower and more variable dose than concentrated supplements. Most clinical nutrition guidance does not single out these foods as dangerous during pregnancy, and the studies raising concern involved chamomile in quantities that could reasonably be called medicinal rather than culinary [1]. That said, very large amounts of parsley have been associated with folkloric use as a uterine stimulant, and excessive intake of any apigenin-rich food during pregnancy is worth discussing with a healthcare provider.
Should I stop taking apigenin if I find out I'm pregnant?
If you are taking an apigenin supplement and discover you are pregnant, the prudent step is to stop the supplement and discuss the timing and dosage with your OB or midwife at the earliest opportunity. There is no emergency protocol needed for typical supplement doses, but given the lack of human safety data, the labor-stimulating effect of oral chamomile in post-term pregnancy [1][2], and the general principle that supplement-level flavonoid doses should not be assumed safe in pregnancy [3], continuing supplementation throughout pregnancy without medical guidance is not advisable. This is informational, not medical advice.
References
- Gholami F et al. Onset of Labor in Post-Term Pregnancy by Chamomile. Iranian Red Crescent medical journal (2016). PMID 28210497
- Heidari-Fard S et al. The effect of chamomile odor on contractions of the first stage of delivery in primpara women: A clinical trial. Complementary therapies in clinical practice (2018). PMID 30057060
- Barenys M et al. Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review. Current drug targets (2017). PMID 26240050
- Meresman GF et al. Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies. Human reproduction update (2021). PMID 33124671
- Fateh AH et al. Prenatal developmental toxicity evaluation of Verbena officinalis during gestation period in female Sprague-Dawley rats. Chemico-biological interactions (2019). PMID 30807743
- Williams JT et al. Systematic review of the impact of ginger extract and alpinetin on pregnancy outcomes in animal models. BMC complementary medicine and therapies (2025). PMID 40380319
- Ożarowski M et al. Pharmacological Effect of Quercetin in Hypertension and Its Potential Application in Pregnancy-Induced Hypertension: Review of In Vitro, In Vivo, and Clinical Studies. Evidence-based complementary and alternative medicine : eCAM (2018). PMID 30622610
- National Center for Complementary and Integrative Health (NIH) Chamomile: Usefulness and Safety. National Center for Complementary and Integrative Health (NIH) source
- Haydée Viola et al. Apigenin, a Component ofMatricaria recutitaFlowers, is a Central Benzodiazepine Receptors-Ligand with Anxiolytic Effects. Planta Medica (1995). PMID 7617761
- Campbell EL et al. The dietary flavonoids apigenin and (-)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA(A) receptors. Biochemical pharmacology (2004). PMID 15451406
- Goutman JD et al. Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. European journal of pharmacology (2003). PMID 12586201
- Carlos Escande et al. Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38. Diabetes (2012). PMID 23172919
- Kramer DJ et al. Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in nutrition (2024). PMID 38476603
- Jay D. Amsterdam et al. Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study. PubMed (2012). PMID 22894890
- Borges G et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free radical biology & medicine (2022). PMID 35452808
- Wang Z et al. Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro. Pharmacology (2016). PMID 27287328
- Fei Lin et al. Inhibitory effect of Selaginella doederleinii hieron on human cytochrome P450. Frontiers in Pharmacology (2023). PMID 36874034
- Kondža M et al. Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids. Molecules (Basel, Switzerland) (2021). PMID 34069400
- Shimada H et al. Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. Journal of biochemical and molecular toxicology (2010). PMID 20806393
- Mastrofini GF et al. Modulating stress and sleep through a multi-compound dietary supplement: a randomized, double-blind, placebo-controlled trial. Journal of the International Society of Sports Nutrition (2026). PMID 42829807
- European Medicines Agency (HMPC) European Union herbal monograph on Matricaria recutita L., flos (EMA/HMPC/55843/2011). European Medicines Agency (HMPC) (2015). source
- European Medicines Agency (HMPC) Assessment report on Matricaria recutita L., flos and aetheroleum (draft, EMA/HMPC/55837/2011). European Medicines Agency (HMPC) (2014). source
- Yao L et al. Apigenin acts as a partial agonist action at estrogen receptors in vivo. European journal of pharmacology (2021). PMID 34048736
- Hiremath SP et al. Antifertility and hormonal properties of flavones of Striga orobanchioides. European journal of pharmacology (2000). PMID 10720651
- Saarinen N et al. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. The Journal of steroid biochemistry and molecular biology (2001). PMID 11595503
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.